Arena Pharmaceuticals Long Term Debt

Arena Pharmaceuticals (ARNA) currently reports a long-term debt of $36M as of December 2021. That compares with $41M in the prior-year period — down 12.3% year over year. Use the charts on this page to explore Arena Pharmaceuticals's long-term debt history and peer comparisons.

Arena Pharmaceuticals's long-term debt decreased from $41M to $36M — a 12.3% year-over-year decrease (period ending December 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arena Pharmaceuticals reported $36M in long-term debt as of December 2021. That compares with $41M in the prior-year period — down 12.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $36M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arena Pharmaceuticals, and consider following ARNA for alerts when major investors trade the stock.

Arena Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $36M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARNA with unrelated industries.